References
- Hong S, Won YJ, Park YR, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52:335-50. https://doi.org/10.4143/crt.2020.206
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
- Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80. https://doi.org/10.1056/NEJMra0802714
- National Comprehensive Cancer Network. NCCN guidelines for non-small cell lung cancer, version 5.2021 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2021 [cited 2021 Aug 18]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
- Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4:792-801. https://doi.org/10.1097/jto.0b013e3181a7716e
- Yang CC, Fong Y, Lin LC, et al. The age-adjusted Charlson comorbidity index is a better predictor of survival in operated lung cancer patients than the Charlson and Elixhauser comorbidity indices. Eur J Cardiothorac Surg 2018;53:235-40. https://doi.org/10.1093/ejcts/ezx215
- Birim O, Kappetein AP, Bogers AJ. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardiothorac Surg 2005;28:759-62. https://doi.org/10.1016/j.ejcts.2005.06.046
- Luchtenborg M, Jakobsen E, Krasnik M, Linklater KM, Mellemgaard A, Moller H. The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patients. Eur J Cancer 2012;48:3386-95. https://doi.org/10.1016/j.ejca.2012.06.012
- Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol 2004;57:597-609. https://doi.org/10.1016/j.jclinepi.2003.11.002
- Donington J, Ferguson M, Mazzone P, et al. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest 2012;142:1620-35. https://doi.org/10.1378/chest.12-0790
- Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT; American College of Chest Physicians. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):161S-177S. https://doi.org/10.1378/chest.07-1359
- Donahoe LL, de Valence M, Atenafu EG, et al. High risk for thoracotomy but not thoracoscopic lobectomy. Ann Thorac Surg 2017;103:1730-5. https://doi.org/10.1016/j.athoracsur.2016.11.076
- Fernando HC, Timmerman R. American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2012;144:S35-8. https://doi.org/10.1016/j.jtcvs.2012.06.003
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. https://doi.org/10.1016/0021-9681(87)90171-8
- Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016;11:39-51. https://doi.org/10.1016/j.jtho.2015.09.009
- Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187-96. https://doi.org/10.1097/SLA.0b013e3181b13ca2
- Puri V, Crabtree TD, Bell JM, et al. National cooperative group trials of "high-risk" patients with lung cancer: are they truly "high-risk"? Ann Thorac Surg 2014;97:1678-85. https://doi.org/10.1016/j.athoracsur.2013.12.028
- Taylor MD, LaPar DJ, Isbell JM, Kozower BD, Lau CL, Jones DR. Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 2014;147:738-46. https://doi.org/10.1016/j.jtcvs.2013.09.064
- Lugg ST, Agostini PJ, Tikka T, et al. Long-term impact of developing a postoperative pulmonary complication after lung surgery. Thorax 2016;71:171-6. https://doi.org/10.1136/thoraxjnl-2015-207697
- Puri V, Patel AP, Crabtree TD, et al. Unexpected readmission after lung cancer surgery: a benign event? J Thorac Cardiovasc Surg 2015;150:1496-505. https://doi.org/10.1016/j.jtcvs.2015.08.067
- Geraci TC, Ng T. When is it safe to operate for lung cancer?: selection of fiscally responsible cardiopulmonary function tests for limited resection (wedge resection and segmentectomy), standard lobectomy, sleeve lobectomy, and pneumonectomy. Thorac Surg Clin 2021;31:255-63. https://doi.org/10.1016/j.thorsurg.2021.04.006
- Bibo L, Goldblatt J, Merry C. Does preoperative pulmonary rehabilitation/physiotherapy improve patient outcomes following lung resection? Interact Cardiovasc Thorac Surg 2021;32:933-7. https://doi.org/10.1093/icvts/ivab011
- Kong M, Zheng H, Ding L, et al. Perioperative pulmonary rehabilitation training (PPRT) can reduce the cost of medical resources in patients undergoing thoracoscopic lung cancer resection: a retrospective study. Ann Palliat Med 2021;10:4418-27. https://doi.org/10.21037/apm-21-478
- Wang X, Wang N, Wang X, et al. Application value of goal-directed fluid therapy with ERAS in patients undergoing radical lung cancer surgery. Am J Transl Res 2021;13:8186-92.